ArticleScientific reports2026
The AHEAD-NLR score: a novel inflammatory-comorbidity integrated tool for predicting long-term mortality in patients with heart failure after acute myocardial infarction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory Signatures from the Complete Blood Count and In-Hospital Mortality in Acute Myocardial Infarction.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The AHEAD score (Atrial fibrillation, Hemoglobin, Elderly age, Abnormal renal function, and Diabetes) has proven valuable for risk stratification in acute heart failure. However, its prognostic utility specifically in the distinct and high-risk population of patients who develop heart failure after an acute myocardial infarction (AMI) remains to be clarified. Current risk assessment tools in this setting often underrepresent the significant role of systemic inflammation, a key driver of adverse remodeling and poor outcomes post-AMI. To address this gap, we incorporated the Neutrophil-to-lymphocyte ratio (NLR), a robust and readily available marker of inflammatory response. The modified AHEAD-NLR score aims to integrate established clinical risk factors with inflammatory activity, thereby addressing a critical limitation of prior tools and potentially offering a more comprehensive prognostic model. A total of 840 patients with heart failure after AMI were enrolled in this study (age 62.55 ± 11.89 years, 81.90% men), with a median follow-up duration of 954 days. The predictive efficacy of the AHEAD score for all-cause mortality was evaluated using Cox regression analysis. The mean AHEAD score of study was 1.05 ± 1.04. After adjusting for age, gender, red cell distribution width (RDW), uric acid, serum potassium, D-dimer, Neutrophil-to-lymphocyte ratio (NLR), and Left ventricular ejection fraction(LVEF), the AHEAD score was still significantly associated with an increased risk of all-cause mortality (hazard ratio and 95% confidence interval: 1.270, 1.019-1.582). In addition, when we constructed a new score, AHEAD-NLR, by incorporating the NLR (≥ 8.16) into the AHEAD score, the net reclassification improvement for predicting all-cause mortality was increased by 19.9%. AHEAD score is an independent predictor of all-cause mortality in patients with HF after AMI. AHEAD-NLR score, which integrates clinical risk factors and inflammatory status, further optimizes risk stratification, offering a more comprehensive prognostic tool for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.